ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 0156 • ACR Convergence 2024

    Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults

    Anurag Goel1, Joshua Tanzer2 and Vinit Gilvaz3, 1The Warren Alpert Medical School of Brown University, Providence, RI, 2Lifespan Biostatistics, Epidemiology, Research Design, and Informatics Core, Providence, RI, 3The Warren Alpert Medical School of Brown University, East Providence, RI

    Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated…
  • Abstract Number: 0549 • ACR Convergence 2024

    Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study

    Nelly Ziade1, Sherif Gamal2, Maroun Aoun3, Ihsane Hmamouchi4, Clementina López Medina5, Maxime Dougados6 and Bassel Elzorkany7, and ASAS-PerSpA, 1Saint-Joseph University, Beirut, Lebanon, 2Cairo University, Cairo, Egypt, 3Saint Joseph University, Beirut, Lebanon, 4Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, 5Reina Sofia University Hospital, Cordoba, Spain, 6Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 7Private (BZRC), Cairo, Egypt

    Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…
  • Abstract Number: 0598 • ACR Convergence 2024

    Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study

    Eva van Geel1, Romy Hansildaar2, Fatih Çoban1, Bas Dijkshoorn1, Maaike Heslinga1, Reinhard Bos3, Mies Korteweg1, Arno Van Kuijk1 and Michael Nurmohamed4, 1Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, 3Medical Center Leeuwarden, Leeuwarden, Netherlands, 4Reade and Amsterdam UMC, Kortenhoef, Netherlands

    Background/Purpose: Psoriatic arthritis (PsA) is associated with metabolic and cardiovascular disease. Studies have suggested that treatment with apremilast is associated with weight loss and other…
  • Abstract Number: 1098 • ACR Convergence 2024

    Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study

    Antonio Avilés1, Zulema Plaza2, Fernando Sánchez-Alonso3, Santos Castañeda4, Benjamin fernandez-Gutierrez5, César Díaz6, Pilar Font7, Olga Martinez8, Emilio Giner9, José Miguel Senabre10, Amalia Rueda11, Ana Perez12, Gines Sanchez13, Carlos Gonzalez14, Javier García15, Javier Llorca16, Miguel Angel Gonzalez-Gay17 and Mariano Andres18, and CARMA project, reserch group., 1Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, 2Fundacion Española de Reumatología, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4Hospital Universitario de la Princesa, Madrid, Spain, 5HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, 6Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 8Hospital Universitario de Salamanca, Zamora, Spain, 9Hospital Royo Villanova, Teruel, Spain, 10Hospital Marina Baixa Alicante, Alicante, Spain, 11Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, 12Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, 13Hospital General de Albacete, Albacete, Spain, 14Hospital Universitario Lucus Augusti; Biodiscovery HULA-USC Group, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS., Lugo, Spain, 15Hospital Universitario 12 de Octubre, Madrid, Spain, 16CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, 17University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 18Hospital General Universitario de Alicante, Alicante, Spain

    Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…
  • Abstract Number: 1455 • ACR Convergence 2024

    Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis

    Fadi Kharouf1, Shangyi Gao2, Ali Alhadri2, Daniel Pereira3, Richard Cook4, Vinod Chandran5 and Dafna Gladman6, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 3University Health Network, Toronto, ON, Canada, 4University of Waterloo, Waterloo, Canada, 5University of Toronto, Toronto, ON, Canada, 6University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Secondary failure to biologic therapy is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). In this study, we aimed to define…
  • Abstract Number: 1478 • ACR Convergence 2024

    Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement

    Xenofon Baraliakos1, Paul Bird2, Atul Deodhar3, Dafna Gladman4, Philip S. Helliwell5, Denis Poddubnyy6, Arthur Kavanaugh7, Mikkel Ostergaard8, Enrique R. Soriano9, Lai-shan Tam10, Soumya Chakravarty11, Evan Leibowitz12, Cinty Gong13, Stephen Xu14, Thomas Fuerst15, Nadeem Saeed16, Robert Landewé17 and Philip Mease18, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 2University of New South Wales, Randwick, NSW, Sydney, New South Wales, Australia, 3Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, 6Charite-Universitatsmedizin Berlin, Berlin, Germany, 7University of California San Diego, La Jolla, CA, 8Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 9Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 10The Chinese University of Hong Kong, New Territories, Hong Kong, 11Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, 12Janssen Scientific Affairs, LLC, Fair Lawn, NJ, 13Janssen Scientific Affairs, Horsham, PA, 14Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, 15Clario, San Mateo, CA, 16Clario, San Mateo, 17Amsterdam University Medical Center, Meerssen, Netherlands, 18Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Patients (pts) with PsA can develop axial inflammation in the SI joints (SIJs) and/or spine. Although validated classification criteria for axial spondyloarthritis exist, established…
  • Abstract Number: 2050 • ACR Convergence 2024

    Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies

    caroline pignon1, Laure Gossec2, Bruno Fautrel3, Clementina López Medina4 and Noemie bibas5, 1Faculté de médecine Créteil, PARIS, France, 2Sorbonne Université, Paris, France, 3INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 4Reina Sofia University Hospital, Cordoba, Spain, 5Sorbonne Université, paris

    Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA), however data on the frequency and consequences of enthesitis are conflicting. To analyze clinical enthesitis in…
  • Abstract Number: 2323 • ACR Convergence 2024

    The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis

    Keith Colaco1, laura bumbulis2, Vinod Chandran1, Richard Cook3, Dafna Gladman4 and Lihi Eder5, 1University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3University of Waterloo, Waterloo, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Biologic therapies, such as tumor necrosis factor-alpha inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) may affect the cardio-metabolic profile of patients with psoriatic arthritis (PsA).…
  • Abstract Number: 2340 • ACR Convergence 2024

    Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening

    Jessica A Walsh1, Shaobo Pei2, Gopi Penmetsa3, Swetha Alexander4, Nga Lori Ly5, Rosario Adriana Molano-Romero4, April Conlon6, Catherine Bakewell7, Soumya Reddy8, Jose Scher9 and Alexis Ogdie10, 1Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 2University of Utah, Thousand Oaks, CA, 3University Of Utah Hospital, Salt Lake City, UT, 4University of Utah Health, Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6University of Utah, Sandy, UT, 7Intermountain Healthcare, Salt Lake City, UT, 8NYU Grossman School of Medicine, New York, NY, 9New York University School of Medicine, New York, NY, 10Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Diagnostic delays are common in psoriatic arthritis (PsA). Screening surveys administered in clinic can identify psoriasis patients at elevated risk for PsA who should…
  • Abstract Number: 2367 • ACR Convergence 2024

    Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies

    Philip Mease1, Denis Poddubnyy2, Rajan Bajracharya3, Barbara Ink3, Alexander Marten4, Ute Massow4, Vishvesh Shende3, Myriam Manente5, Luke Peterson6, Katy White3, Peter Nash7 and Lianne S Gensler8, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Charite-Universitatsmedizin Berlin, Berlin, Germany, 3UCB Pharma, Slough, United Kingdom, 4UCB Pharma, Monheim am Rhein, Germany, 5UCB Pharma, Braine-l'Alleud, Belgium, 6UCB Pharma, Morrisville, NC, 7School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, 8Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…
  • Abstract Number: 0187 • ACR Convergence 2024

    Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
  • Abstract Number: 0550 • ACR Convergence 2024

    Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study

    Nelly Ziade1, Ihsane Hmamouchi2, Clementina López Medina3, Maroun Aoun4, Sherif Gamal5, Maxime Dougados6 and Bassel Elzorkany7, and ASAS-PerSpA, 1Saint-Joseph University, Beirut, Lebanon, 2International University of Rabat, Rabat, Morocco, 3Reina Sofia University Hospital, Cordoba, Spain, 4Saint Joseph University, Beirut, Lebanon, 5Cairo University, Cairo, Egypt, 6Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 7Private (BZRC), Cairo, Egypt

    Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…
  • Abstract Number: 0600 • ACR Convergence 2024

    Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies

    Laure Gossec1, Dafna Gladman2, Laura Coates3, Maarten de Wit4, Barbara Ink5, Rajan Bajracharya5, Jason Coarse6, Jérémy Lambert7 and Ana-Maria Orbai8, 1Sorbonne Université, Paris, France, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 4Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, 5UCB Pharma, Slough, United Kingdom, 6UCB Pharma, Morrisville, NC, 7UCB Pharma, Colombes, France, 8Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained reductions in disease impact of PsA, assessed…
  • Abstract Number: 1128 • ACR Convergence 2024

    A Meta-Analysis of Statin Efficacy in Controlling Disease Activity in Psoriasis

    Barbara Abreu Lopez1, Ernesto Calderon Martinez2, Tania Siu Xiao3, Zulma Sosa Carcamo4, Alejandra Maria Aleman Reyes5, Felix Ricardo Bonilla Bonilla6, María Isabel Murillo Pineda5, Edgar Josué Sanabria Herrera7, Alberto Ayala Aguilar8, Adreina Del Valle Rojas Marron9, Valentina Contreras Duran,10, Kevin J. Lopez Romero11 and Marcela Garzon12, 1Universidad de Carabobo, Carabobo, Venezuela, 2The University of Texas Science Medical Center at Houston, Tomball, 3Thomas Jefferson University Hospital, Philadelphia, 4Universidad Evangélica de El Salvador, San Salvador, El Salvador, 5Universidad Católica de Honduras, Tegucigalpa, Honduras, 6Hospital Militar Central, San Salvador, El Salvador, 7Universidad Nacional Autónoma de Honduras, Tegucigalpa, 8Baylor College of Medicine, Houston, 9Universidad de Oriente Núcleo Anzoátegui, Barcelona, Venezuela, 10MD Anderson Cancer Center, Texas, Houston, 11Universidad de El Salvador, San Salvador, El Salvador, 12Universidad de Los Andes, Bogotá, Colombia

    Background/Purpose: Psoriasis is a chronic inflammatory skin disorder that is associated with an increased risk of cardiovascular diseases. Chronic inflammation in psoriasis can produce excessive…
  • Abstract Number: 1456 • ACR Convergence 2024

    Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort

    Lija James1, Elnaz Saeedi2, Jean-Guillaume Letarouilly1, Nicola Gullick3, Anne Francis2, Deepak Jadon4, William Tillett5, Yvonne Sinomati2, Laura Tucker1, Nadia Mian2, Ines Rombach2, Ioana Marian2, Maria Sofia Massa2 and Laura Coates6, 1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Oxford Clinical Trials Research Unit, University of Oxford, Oxford, United Kingdom, 3Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, 4Cambridge University, Cambridge, United Kingdom, 5Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 6University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic musculoskeletal disease, which can lead to progressive joint pain, joint destruction, and loss of function. Evidence suggests that…
  • 1
  • 2
  • 3
  • …
  • 81
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology